Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of +219.14% and +2.85%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?